Cargando…

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes

INTRODUCTION: Many people with type 1 diabetes (T1DM) continue to run high HbA1c levels with an associated elevated risk of cardiovascular events and increased mortality. We describe here how adjunctive prescription of an SGLT2 inhibitor has improved the glycaemic control of several people with T1DM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yadegarfar, Ghasem, Livingston, Mark, Cortes, Gabriela, Alshames, Ramadan, Leivesley, Kate, Metters, Ann, Horne, Linda, Steele, Tom, Heald, Adrian H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189611/ https://www.ncbi.nlm.nih.gov/pubmed/34124604 http://dx.doi.org/10.1097/XCE.0000000000000248

Ejemplares similares

Mortality Rate Associated with Diabetes: Outcomes From a General Practice Level Analysis in England Using the Royal College of General Practitioners (RCGP) Database Indicate Stability Over a 15 Year Period
por: Heald, Adrian, et al.
Publicado: (2022)

Success story of GLP-1 agonist (Liraglutide) treatment in someone with type 1 diabetes: a life transformed
por: Heald, Adrian H., et al.
Publicado: (2023)

Male hypogonadism: 14‐year prospective outcome in 550 men with type 2 diabetes
por: Malipatil, Nagaraj S., et al.
Publicado: (2019)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
por: Sokolov, Victor, et al.
Publicado: (2023)

Recalibration of thinking about adrenocortical function assessment: how the ‘random’ cortisol relates to the short synacthen test results
por: Michaelidou, Maria, et al.
Publicado: (2021)

Analysis of Continuous Blood Glucose Data in People with Type 1 Diabetes (T1DM) After COVID-19 Vaccination Indicates a Possible Link Between the Immune and the Metabolic Response
por: Heald, Adrian H., et al.
Publicado: (2021)

The risk factors potentially influencing risk of serious illness/death in people with diabetes, following SARS-CoV-2 infection: What needs to be done from here
por: Heald, Adrian H., et al.
Publicado: (2021)

Real‐world practice level data analysis confirms link between variability within Blood Glucose Monitoring Strip (BGMS) and glycosylated haemoglobin (HbA1c) in Type 1 Diabetes
por: Heald, Adrian H., et al.
Publicado: (2018)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial
por: Jiang, Lan-lan, et al.
Publicado: (2021)

Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
por: Iijima, Yasuhiro, et al.
Publicado: (2023)

Analysis of English general practice level data linking medication levels, service activity and demography to levels of glycaemic control being achieved in type 2 diabetes to improve clinical practice and patient outcomes
por: Heald, Adrian, et al.
Publicado: (2019)

Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
por: Araki, Eiichi, et al.
Publicado: (2021)

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
por: Vega-Hernandez, Gabriela, et al.
Publicado: (2017)

No Difference in Mood and Quality of Life in DHEA-S Deficient Adults with Addison’s Disease vs. Type 2 Diabetes Patients with Normal DHEA-S Levels: Implications for Management of These Conditions
por: Heald, Adrian H., et al.
Publicado: (2017)

Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation
por: Stedman, Mike, et al.
Publicado: (2020)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
por: Saeed, Mujahid A, et al.
Publicado: (2014)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes
por: Bletsa, Evdoxia, et al.
Publicado: (2021)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Age of people with type 2 diabetes and the risk of dying following SARS‐CoV‐2 infection
por: Tian, Zixing, et al.
Publicado: (2021)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
por: Imamura, Akira, et al.
Publicado: (2013)

Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
por: Salvo, Marissa C, et al.
Publicado: (2014)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos, Ioannis, et al.
Publicado: (2019)

LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes
por: Ghanim, Husam, et al.
Publicado: (2022)

Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2023)

Knowledge, attitude, and practice of parents of 7–12-year-old children regarding fissure sealant therapy and professional fluoride therapy
por: Tahani, Bahareh, et al.
Publicado: (2017)

The prevalence of preconception care, its relation with recipients’ individuality, fertility, and the causes of lack of checkup in women who gave birth in Isfahan hospitals in 2016
por: Shadab, Parisa, et al.
Publicado: (2017)

Predictors of Breast Cancer Screening behavior in Women aged 20-69 Referred to Public Health Centers: A Cross-Sectional Study in Isfahan Province
por: Ebrahimi, Fatemeh, et al.
Publicado: (2022)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bap49jbg7b5ms08777frfcn78d